North America Bloodstream Infection Testing Market to Hit Around USD 464.04 Million by 2033
The North America bloodstream infection testing market size was exhibited at USD 319.58 million in 2023 and is projected to hit around USD 464.04 million by 2033, growing at a CAGR of 3.8% during the forecast period 2024 to 2033.
Download Free Sample Copy for Better Understanding@ https://www.novaoneadvisor.com/report/sample/8382
North America Bloodstream Infection Testing Market Key Takeaways:
Increasing demand for advanced bloodstream infection testing methods and a rising number of CROs and forensic and research laboratories are among the major factors expected to drive growth in the bloodstream infection testing market. Moreover, the introduction of culture-independent tests holds significant promise in improving patient management with bloodstream infections (BSI) as these methods can reduce the time required for test results and enhance their accuracy. Furthermore, the high prevalence of STIs and tuberculosis in the region is also anticipated to propel the bloodstream infection testing market growth.
According to CDC data, reported cases of STIs such as chlamydia, syphilis, and gonorrhea increased between 2020 and 2021. According to the survey, more than 2.5 million cases were reported during this period and gonorrhea rates rose by over 4%, while syphilis rates surged, increasing by nearly 32% for combined stages of the infection. Congenital syphilis cases also saw a significant 32% increase, leading to 220 stillbirths and infant deaths. Chlamydia rates increased by approximately 4%, as per the report.
The U.S. bacterial infection testing market has witnessed significant trends in recent years. With increasing awareness about healthcare-associated infections and the rise in drug-resistant bacteria, there has been a growing demand for accurate and rapid diagnostic tests. Molecular diagnostic techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), have gained prominence due to their high sensitivity and specificity.
Additionally, there is a shift towards point-of-care testing, allowing for faster diagnosis and treatment decisions. The market also is seeing a rising adoption of automated systems and integrated platforms, streamlining the testing process and improving efficiency. Overall, the U.S. bacterial infection testing market is expected to continue its growth trajectory fueled by technological advancements and the need for prompt and accurate diagnostics.
Another significant trend in the U.S. bacterial infection testing market is the increasing adoption of MALDI-TOF mass spectrometry. MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight) is a powerful technology that enables rapid identification of bacteria and their antibiotic resistance profiles. It offers advantages such as high accuracy, speed, and cost-effectiveness compared to traditional culture-based methods. With its ability to identify a wide range of bacterial species within minutes, MALDI-TOF has become an essential tool in clinical laboratories for diagnosing bacterial infections. Its widespread implementation is driven by the need for timely and targeted treatment decisions, especially in sepsis and antibiotic-resistant infections.
As a result, the U.S. bacterial infection testing market is witnessing a growing demand for MALDI-TOF mass spectrometry platforms. For instance, in February 2023, Bruker Corporation introduced the timsTOF MALDI PharmaPulse system, an advanced high-end solution designed for unbiased and efficient high-throughput screening (HTS) and ultra-high-throughput screening (uHTS) utilizing label-free mass spectrometry. This innovative system enables complete and rapid analysis, revolutionizing the screening process in the pharmaceutical industry. With the timsTOF MALDI PharmaPulse system, researchers and scientists have access to a powerful tool that enhances productivity and accuracy, ultimately driving drug discovery and development advancements.
North America Bloodstream Infection Testing Market By Product Insights
The reagents and consumables segment accounted for the largest revenue share of 89.12% in 2023. The segment is also expected to expand at the fastest growth rate over the forecast period. The segment's growth is driven by the easy availability and frequent purchase of screening products for donors and recipients. Moreover, the market is propelled by the wide range of blood grouping, typing, and donor screening reagents, kits, and assays offered by North American and local manufacturers.
North America Bloodstream Infection Testing Market By Sample Type Insights
The blood culture segment accounted for the largest revenue share of 75.81% in 2023 and is expected to witness the fastest CAGR over the forecast period. Blood culture testing has continued to evolve with technological advancements. The introduction of automated blood culture systems and faster detection methods have enhanced result efficiency and turnaround time, further cementing the segment’s dominance.
For instance, in October 2023, BD, a global medical technology company, and Magnolia Medical Technologies, Inc. entered a commercial agreement. The collaboration aims to assist U.S. hospitals in reducing blood culture contamination, enhancing testing accuracy, and ultimately improving clinical outcomes. Therefore, such initiatives with effective tools and technologies enhance the reliability and efficiency of blood culture testing, thereby boosting the demand for such methods.
North America Bloodstream Infection Testing Market By Technology Insights
The PCR segment held the largest revenue share of 60.7% in 2023 in the North America bloodstream infection testing market and is expected to expand at the fastest CAGR over the forecast period. The introduction of technologically advanced PCR tests, government initiatives, increasing prevalence of targeted diseases, and application expansion of existing technologies are expected to drive segment growth over the forecast period.
North America Bloodstream Infection Testing Market By End-user Insights
The hospital and diagnostic centers segment accounted for the largest revenue share of 45.85% in 2023 and is expected to witness the fastest CAGR from 2024 to 2033. Hospitals often have R&D departments dedicated to studying bloodstream infections and developing new diagnostic tools, therapies, and preventive strategies. Their expertise and resources contribute to advancements in the field, further solidifying their position in the bloodstream infection testing market. Hospitals also possess advanced healthcare infrastructure, including well-equipped laboratories, diagnostic facilities, and skilled healthcare professionals. This allows for efficient diagnosis, monitoring, and treatment of bloodstream infections, leading to better patient outcomes.
North America Bloodstream Infection Testing Market By Regional Insights
The U.S. dominated the regional market for bloodstream infection testing and accounted for the largest revenue share of 81.71% in 2023. This is due to the increasing awareness, favorable reimbursement policies, and increasing strategic initiatives and product launches by the major companies operating in the country. In October 2023, BD, a global medical technology company, and Magnolia Medical Technologies, Inc. entered a commercial agreement. The collaboration aims to assist U.S. hospitals in reducing blood culture contamination, enhancing testing accuracy, and ultimately improving clinical outcomes.
Some of the prominent players in the North America bloodstream infection testing market include:
Reasons to Purchase this Report
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the North America bloodstream infection testing market
Product
Sample Type
Technology
End-user
Regional
Quick Buy This Premium Report From Here: https://www.novaoneadvisor.com/report/checkout/8382
Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com
You can place an order or ask any questions, please feel free to [email protected]| +1 9197 992 333
领英推荐
About US
Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.
Connect with Us
Address: Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
IND Address: 2nd Floor,Shreeleela Plaza, Baner Road, Pune, Maharashtra - 411045
Call: USA - + 1 804 441 9344| IND - + 91 87933 22019 | Europe: +44 2080772818
Nova One Advisor Group Offer Other Reports:
Cell Therapy Market Size and Forecast:?The global?cell therapy market size was exhibited at USD 4.85 billion in 2023 and is projected to hit around USD 37.42 billion by 2033, growing at a CAGR of 22.67% during the forecast period 2024 to 2033.
Gene Therapy Market Size and Forecast?:?The global?gene therapy market size was exhibited at USD 8.75 billion in 2023 and is projected to hit around USD 52.40 billion by 2033, growing at a CAGR of 19.6% during the forecast period 2024 to 2033.
Cell And Gene Therapy Manufacturing Market Size and Forecast:?The global?cell and gene therapy manufacturing market size was estimated at USD 9.95 billion in 2023 and is projected to hit around USD 106.03 billion by 2033, growing at a CAGR of 26.7% during the forecast period from 2024 to 2033.
Cell and Gene Therapy Market?Size and Forecast:?The global?cell and gene therapy market size was estimated at USD 18.13 billion in 2023 and is projected to hit around USD 97.33 billion by 2033, growing at a CAGR of 18.3% during the forecast period from 2024 to 2033.
U.S. Cell Therapy Market Size and Forecast:?The?U.S. cell therapy market size was estimated at USD 2.88 billion in 2023 and is projected to hit around USD 19.67 billion by 2033, growing at a CAGR of 21.18% during the forecast period from 2024 to 2033.
U.S. Gene Therapy Market Size and Forecast:?The?U.S. gene therapy market size?was estimated at USD 3.19 billion in 2023 and is projected to hit around USD 18.50 billion by 2033, growing at a CAGR of 19.22% during the forecast period from 2024 to 2033.
T-cell Therapy Market Size and Forecast:?The global?T-Cell therapy market size?was exhibited at USD 3.85 billion in 2023 and is projected to hit around USD 79.62 billion by 2033, growing at a CAGR of 35.38% during the forecast period 2024 to 2033.
Cancer Immunotherapy Market?Size and Forecast:?The global?cancer immunotherapy market?size was valued at USD 126.19 billion in 2023 and is projected to surpass around USD 296.01 billion by 2033, registering a CAGR of 8.9% over the forecast period of 2024 to 2033.
Immunotherapy Drugs Market?:?The global?immunotherapy drugs market size was valued at USD 240.19 billion in 2023 and is projected to surpass around USD 1,300.38 billion by 2033, registering a CAGR of 18.4% over the forecast period of 2024 to 2033.
Clinical Trials Market Size and Forecast:?The?global clinical trials market size was estimated at USD 81.90 billion in 2023 and is projected to hit around USD 153.59 billion by 2033, growing at a CAGR of 6.49% during the forecast period from 2024 to 2033.
Biologics Market Size and Forecast: The?global biologics market size was estimated at USD 511.04 billion in 2023 and is projected to hit around USD 1,374.51 billion by 2033, growing at a CAGR of 10.4% during the forecast period from 2024 to 2033.
Biotechnology Market Size and Forecast:? The?global biotechnology market size was estimated at USD 1.54 Trillion in 2023 and is projected to hit around USD 5.68 Trillion by 2033, growing at a CAGR of 13.95% during the forecast period from 2024 to 2033.
Oncology? Market Size and Forecast: The?global oncology market size was estimated at USD 222.36 billion in 2023 and is projected to hit around USD 521.60 billion by 2033, growing at a CAGR of 8.9% during the forecast period from 2024 to 2033.
Cell And Gene Therapy Clinical Trials?Market Size and Forecast: The global cell and gene therapy clinical trials market size reached USD 11.62 billion in 2023 and is projected to hit around USD 47.40 billion by 2033, expanding at a CAGR of 15.09% during the forecast period from 2024 to 2033.
U.S. Clinical Trials Market Size and Forecast:?The?U.S. clinical trials market size was valued at USD 25.81 billion in 2023 and is projected to surpass around USD 41.57 billion by 2033, registering a CAGR of 4.88% over the forecast period of 2024 to 2033.
Active Pharmaceutical Ingredient CDMO Market:?The global active pharmaceutical ingredient CDMO market size was valued at USD 119.80 billion in 2023 and is anticipated to reach around USD 249.22 billion by 2033, growing at a CAGR of 7.6% from 2024 to 2033.
U.S. Pharmaceutical Market?:?The U.S. pharmaceutical market size was valued at USD 602.19 billion in 2023 and is projected to surpass around USD 1,093.79 billion by 2033, registering a CAGR of 6.15% over the forecast period of 2024 to 2033.
Viral Vector And Plasmid DNA Manufacturing Market:?The global viral vector and plasmid DNA manufacturing market size?was valued at USD 6.19 billion in 2023 and is anticipated to reach around USD 39.30 billion by 2033, growing at a CAGR of 20.3% from 2024 to 2033.
U.S. Viral Vector And Plasmid DNA Manufacturing Market ;?The U.S. viral vector and plasmid DNA manufacturing market size was valued at USD 2.45 billion in 2023 and is expected to be worth around USD 15.30 billion by 2033, with a registered CAGR of 20.1% during forecast period 2024 to 2033.
Compounding Pharmacies Market :?The global compounding pharmacies market size?was valued at USD 16.19 billion in 2023 and is anticipated to reach around USD 30.97 billion by 2033, growing at a CAGR of 6.7% from 2024 to 2033.
U.S. Compounding Pharmacies Market?:?The U.S. compounding pharmacies market size?is projected to be worth around USD 10.76 billion by 2033 from USD 6.31 billion in 2024, at a CAGR of 6.1% from 2024 to 2033.
Antibiotics Market: The?global antibiotics market size?was valued at USD 51.19 billion in 2023 and is projected to surpass around USD 85.80 billion by 2033, registering a CAGR of 5.3% over the forecast period of 2024 to 2033.
Biologics Market :?The?global biologics market size was estimated at USD 511.04 billion in 2023 and is projected to hit around USD 1,374.51 billion by 2033, growing at a CAGR of 10.4% during the forecast period from 2024 to 2033.
Biotechnology Market:?The?global biotechnology market size was estimated at USD 1.54 Trillion in 2023 and is projected to hit around USD 5.68 Trillion by 2033, growing at a CAGR of 13.95% during the forecast period from 2024 to 2033.
Next Generation Sequencing Market?:?The?global next generation sequencing market size was estimated at USD 9.19 billion in 2023 and is projected to hit around USD 66.04 billion by 2033, growing at a CAGR of 21.8% during the forecast period from 2024 to 2033.
Genome Editing Market ;?The?global genome editing market size?was valued at USD 8.45 billion in 2023 and is anticipated to reach around USD 40.48 billion by 2033, growing at a CAGR of 16.96% from 2024 to 2033.
U.S. Genome Editing Market:?The?U.S. genome editing market size was estimated at USD 3.55 billion in 2023 and is projected to hit around USD 16.49 billion by 2033, growing at a CAGR of 16.6% during the forecast period from 2024 to 2033.
U.S. Gene Synthesis Market?:?The?U.S. Gene Synthesis market size was valued at USD 700.90 million in 2023 and is projected to surpass around USD 3,118.73 million by 2033, registering a CAGR of 16.1% over the forecast period of 2024 to 2033.
Biopharmaceutical Market :?The global?Biopharmaceutical market size accounted for USD 327.46 billion in 2022 and is estimated to achieve a market size of USD 1,101.77 billion by 2032 growing at a CAGR of 12.9% from 2023 to 2032.
Immunotherapy Drugs Market?:?The?global immunotherapy drugs market size was valued at USD 240.19 billion in 2023 and is projected to surpass around USD 1,300.38 billion by 2033, registering a CAGR of 18.4% over the forecast period of 2024 to 2033.
Cancer Immunotherapy Market:?The global cancer immunotherapy market size was valued at USD 126.19 billion in 2023 and is projected to surpass around USD 296.01 billion by 2033, registering a CAGR of 8.9% over the forecast period of 2024 to 2033.
U.S. Plasmid DNA Manufacturing Market?:?The U.S. plasmid DNA manufacturing market size?was valued at USD 711.90 million in 2023 and is projected to surpass around USD 4,885.15 million by 2033, registering a CAGR of 21.24% over the forecast period of 2024 to 2033.
U.S. Precision Medicine Market?:?The?U.S. precision medicine market size was valued at USD 24.95 billion in 2023 and is projected to reach around USD 76.12 billion by 2033, registering a CAGR of 11.80% from 2024 to 2033.